OKG-0502

**OKG-0502** is an investigational fixed-dose ophthalmic combination developed by Okogen for **adenoviral conjunctivitis**. It combines the broad-spectrum antiviral ranpirnase, developed by Okogen as OKG-0301 for ophthalmic use, with an undisclosed ocular decongestant. Ranpirnase is an extracellular ribonuclease that enters cells and suppresses viral replication through intracellular RNA degradation; the decongestant component is intended to reduce visible and symptomatic manifestations of conjunctivitis, including conjunctival hyperemia. Public sources do not identify the specific decongestant ingredient, final dosage form, or a nonproprietary name for the combination.